UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934
(Amendment No. )*

 

Clementia Pharmaceuticals Inc.

(Name of Issuer)

Common Stock, no par value

(Title of Class of Securities)

185575107

(CUSIP Number)

December 31, 2017

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o  Rule 13d-1(b) 
   
o  Rule 13d-1(c) 
   
x  Rule 13d-1(d) 

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

CUSIP No. 185575107 
 
  1. 

Names of Reporting Persons

BDC Capital Inc.

 

I.R.S. Identification Nos. of above persons (entities only). 

  

       
  2.   Check the Appropriate Box if a Member of a Group (See Instructions) 
     
    (a)

o

 

    (b)

o

 

      Not Applicable 
       
  3. 

SEC Use Only

 

       
  4.  Citizenship or Place of Organization

Canadian 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

 

5. 

Sole Voting Power
5,497,607

 

 
6.

Shared Voting Power
0

 

 
7.

Sole Dispositive Power
5,497,607

 

 
8.

Shared Dispositive Power
0

 

 

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
5,497,607

 

       

 

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o

 

       

 

 

11.

Percent of Class Represented by Amount in Row (9)
17.33% (1)

 

       

 

 

12.

Type of Reporting Person (See Instructions)
CO

 

 

(1) This percentage is calculated based upon 31,717,584 common shares outstanding as set forth in the Issuer’s Form 6-K filed with the Securities and Exchange Commission on November 13, 2017.

2

Item 1. 
 
  (a) 

Name of Issuer
Clementia Pharmaceuticals Inc. (the “Issuer”) 

 

  (b) 

Address of Issuer’s Principal Executive Offices
4150 Sainte-Catherine Street West, Suite 550, Montreal, Quebec, Canada H3Z 2Y5 

 

 
Item 2. 
 
  (a) 

Name of Person Filing
BDC Capital Inc. 

 

  (b) 

Address of Principal Business Office or, if none, Residence
5 Place Ville Marie, Suite 400
Montreal, Québec, Canada H3B 5E7 

 

  (c) 

Citizenship
Canadian 

 

  (d) 

Title of Class of Securities
Common stock, no par value per share (the “Common Stock”). 

 

  (e) 

CUSIP Number
The CUSIP number of the Common Stock is 185575107. 

 

 

Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: 
       
  (a)  o  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); 
       
  (b)  o  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); 
       
  (c)  o  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); 
       
  (d)  o  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); 
       
  (e)  o  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); 
       
  (f)  o  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); 
       
  (g)  o  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); 
       
  (h)  o  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); 
       
  (i)  o  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); 
       
  (j)  o  A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J); 
       
  (k)  o  Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution:____________________________ 
       
    Not Applicable. 
3

Item 4.  Ownership
 
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
 
  (a)

Amount beneficially owned: 5,497,607 shares

 

  (b)

Percent of class: 17.33%

 

  (c)

Number of shares as to which the person has:

 

    (i)

Sole power to vote or to direct the vote 5,497,607 shares

 

    (ii)

Shared power to vote or to direct the vote Not applicable

 

    (iii)

Sole power to dispose or to direct the disposition of 5,497,607 shares

 

    (iv)

Shared power to dispose or to direct the disposition of Not applicable

 

 

Item 5. Ownership of Five Percent or Less of a Class
   
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.
 
Item 6. Ownership of More than Five Percent on Behalf of Another Person
   
Not applicable
 
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
   
Not applicable
 
Item 8. Identification and Classification of Members of the Group
   
Not applicable
 
Item 9. Notice of Dissolution of Group
   
Not applicable

4
Item 10. Certification

 

Signature

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

  February 14, 2018
  Date
   
  /s/ Jean-Francois Pariseau
  Signature
   
  Jean-Francois Pariseau, Partner, BDC Capital Inc.
  Name/Title
5